{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:23253564",
      "entity_text" : "morphine",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5360515",
      "entity_text" : "naltrexone",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "There are reports on naltrexone induced withdrawal syndrome in opioid dependent patients.23 On the other hand, it is suggested that opioid antagonists in low doses are useful in the treatment of opioid withdrawal.24 Data also suggest that naltrexone in low doses could be used to prevent intolerable morphine adverse events25 or even inhibit the development of opioid tolerance.26 A more controversial explanation to the reduction in number of DDDs on opioids is that the patients experienced therapeutic effects against their medical condition.",
  "reading_complete" : "2020-08-05T21:55:18Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T21:54:27Z",
  "trigger" : "prevent",
  "evidence" : [ "naltrexone in low doses could be used to prevent intolerable morphine" ],
  "pmc_id" : "5485080",
  "score" : 0
}